TSE:4568Pharmaceuticals
Could Daiichi Sankyo (TSE:4568) and Partner’s Push Into Protein Targets Signal a New R&D Strategy?
General Proximity announced a collaboration with Daiichi Sankyo’s Boston Research Institute to apply its OmniTAC discovery platform to identify new targets in cancer treatment, while also advancing programs in other disease areas.
This partnership highlights Daiichi Sankyo’s continued investment in next-generation oncology research and its effort to address protein targets previously considered undruggable.
We’ll examine how this expansion into novel protein targeting could reshape Daiichi...